title: Immunoproteasome in animal models of Duchenne muscular dystrophy.
abstract: Increased proteasome activity has been implicated in the atrophy and deterioration associated with dystrophic muscles of Duchenne muscular dystrophy (DMD). While proteasome inhibitors show promise in the attenuation of muscle degeneration, proteasome inhibition-induced toxicity was a major drawback of this therapeutic strategy. Inhibitors that selectively target the proteasome subtype that is responsible for the loss in muscle mass and quality would reduce side effects and be less toxic. This study examined proteasome activity and subtype populations, along with muscle function, morphology and damage in wild-type (WT) mice and two murine models of DMD, dystrophin-deficient (MDX) and dystrophin- and utrophin-double-knockout (DKO) mice. We found that immunoproteasome content was increased in dystrophic muscles while the total proteasome content was unchanged among the three genotypes of mice. Proteasome proteolytic activity was elevated in dystrophic muscles, especially in DKO mice. These mice also exhibited more severe muscle atrophy than either WT or MDX mice. Muscle damage and regeneration, characterized by the activity of muscle creatine kinase in the blood and the percentage of central nuclei were equally increased in dystrophic mice. Accordingly, the overall muscle function was similarly reduced in both dystrophic mice compared with WT. These data demonstrated that there was transformation of standard proteasomes to immunoproteasomes in dystrophic muscles. In addition, DKO that showed greatest increase in proteasome activities also demonstrated more severe atrophy compared with MDX and WT. These results suggest a putative role for the immunoproteasome in muscle deterioration associated with DMD and provide a potential target for therapeutic intervention.
authors.affiliation: Department of Physical Therapy, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan.
authors.forename: Chiao-Nan Joyce
authors.initials: CN
authors.lastname: Chen
authors.forename: Ted G
authors.initials: TG
authors.lastname: Graber
authors.forename: Wendy M
authors.initials: WM
authors.lastname: Bratten
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Ferrington
authors.forename: LaDora V
authors.initials: LV
authors.lastname: Thompson
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D007162:Immunoproteins / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D018482:Muscle, Skeletal / Q000201:enzymology / Q000276:immunology / Q000378:metabolism* / Q000503:physiopathology; D009137:Muscular Dystrophy, Animal / Q000201:enzymology / Q000276:immunology / Q000378:metabolism* / Q000503:physiopathology; D020388:Muscular Dystrophy, Duchenne / Q000201:enzymology / Q000276:immunology / Q000378:metabolism* / Q000503:physiopathology; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*
chemical_list: D007162:Immunoproteins; D046988:Proteasome Endopeptidase Complex